| Ytd | 11.58% | |
| 1y | 11.06% |
| Open | 280.27 | Prev Close | 279.40 | Low | 277.61 | High | 281.56 | Mkt Cap | 22.91B |
| Vol | 230.17K | Avg Vol | 664.34K | EPS | 16.85 | P/E | 16.58 | Forward P/E | 15.82 |
| Beta | 0.89 | Short Ratio | 4.43 | Inst. Own | 101.11% | Dividend | 2.88 | Div Yield | 1.02 |
| Ex Div Date | 08-28 | Earning | 07-30 | 50-d Avg | 266.45 | 200-d Avg | 267.28 | 1yr Est | 312.35 |
LH News
LH heads into Q2 earnings results with expectations for higher revenues and EPS, as diagnostics, spe
Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combinati
California Public Employees Retirement System decreased its position in Labcorp Holdings Inc. (NYSE:
D.A. Davidson and CO. increased its holdings in shares of Labcorp Holdings Inc. (NYSE: LH) by 17.9%
Labcorp remains a buy consideration, leveraging a successful rollup strategy in a fragmented laborat
B of A Securities analyst Michael Ryskin maintains Labcorp Holdings (NYSE:LH) with a Buy and rais
Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the
First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated
The trial will evaluate approaches to increase germline genetic testing among at-risk family members
New pharmacogenomic test detects all DPYD variants recommended by the Association for Molecular Path
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalize
Labcorp's full test menu will be available through Epic's Aura platformIntegration builds on
Labcorp shares rise after Q1 earnings beat and higher guidance, supported by diagnostics growth and
Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $17.55-$18.25 to $17.70-$18.35 vs $17
Labcorp Holdings (NYSE:LH) raises FY2026 Adj EPS guidance from $17.55-$18.25 to $17.70-$18.35 vs $17
Laboratory Corp (NYSE:LH) reported quarterly earnings of $4.25 per share which beat the analyst cons
KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) are the f
Tech stocks hit new highs as the Nasdaq 100 rallies 0.7% midday. Investors eye a Fed rate cut, Trump
On Tuesday, 838 companies hit new 52-week lows.
On Friday, 404 stocks made new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
The latest round of 13F filings from institutional investors is out, revealing to the world the stoc
Before 10 a.m. ET on Tuesday, 166 companies hit new 52-week highs.
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Highs On Wednesday